Carlyle to Acquire Baxter's Kidney Care Segment (Vantive) for $3.8B

GoodRx Acquires vitaCare

April 14, 2022

Healthcare Services

GoodRx has completed its acquisition of vitaCare for $150 million in cash plus up to $7 million contingent on vitaCare's 2023 performance. The deal adds a tech-enabled pharmacy services platform to GoodRx's capabilities, expanding its Pharma Manufacturer Solutions and enabling more efficient patient access, fulfillment, and adherence for brand medications.

CVC Acquires Therakos Business from Mallinckrodt for $925M

August 5, 2024

Medical Devices

CVC Capital Partners Fund IX agreed to acquire the Therakos extracorporeal photopheresis business from Mallinckrodt plc for $925 million in a carve-out transaction. CVC said it will invest in further research, indication expansion and geographic growth of Therakos while key Therakos employees will transition with the business; Mallinckrodt will use proceeds to substantially reduce net debt.

Novartis Acquires Anthos Therapeutics for Up to $3.1 Billion

February 11, 2025

Biotechnology

Novartis has completed the acquisition of Anthos Therapeutics, a Blackstone Life Sciences–backed clinical-stage biopharmaceutical company, in a deal valued at up to $3.1 billion, including $925 million paid upfront. The acquisition gives Novartis ownership of abelacimab, a Phase 3 factor XI inhibitor being developed to prevent stroke and cancer-associated thrombosis, with remaining milestone payments contingent on regulatory and commercial outcomes.

Pharos Capital Acquires Vantage Outsourcing to Build Ophthalmology Services Platform

September 22, 2021

Healthcare Services

Pharos Capital Group has acquired Vantage Outsourcing, a cataract surgical support services provider headquartered in Effingham, Illinois. Pharos will partner with industry executive Bradley Hill and work with Vantage's existing leadership—co-founder and CEO Ann Deters and President Chris Swing (who retain minority stakes)—to build a broader surgical support services platform across ophthalmology and other specialties.

KKR-backed Biosynth Carbosynth Acquires vivitide; Ampersand Rolls Over Stake

March 17, 2022

Biotechnology

KKR has invested in Biosynth Carbosynth through its Health Care Strategic Growth Fund II, and Biosynth Carbosynth has acquired vivitide, a global provider of custom peptides and antibody services. Existing owner Ampersand Capital Partners rolled over its entire stake and will be a substantial minority shareholder in the combined global life‑sciences reagents and custom synthesis platform to accelerate geographic expansion, broaden capabilities, and expand the product portfolio.

Eli Lilly Acquires Verve Therapeutics

July 25, 2025

Biotechnology

Eli Lilly and Company completed the acquisition of Verve Therapeutics, a Boston-based clinical-stage developer of one-time gene-editing therapies for cardiovascular disease. Lilly said the deal will integrate Verve's genetic-medicine programs into its cardiometabolic research to advance potential lifelong cardiovascular risk–reduction treatments.